{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:31:29Z","timestamp":1791232289194,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Lecanemab was approved for early Alzheimer's disease in Japan, with \u2248 6000 patients treated in the first year post approval. This study explores real\u2010world practices, challenges, and potential solutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We conducted an anonymized online survey of clinical specialists authorized to prescribe lecanemab, obtaining responses from 311 specialists who collectively treated 3259 patients with lecanemab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      A majority of respondents (79%) reported wait times of \u2264 3 months from first consultation to initial infusion. One fourth reported tight outpatient space and staffing and significantly lower capacity of treatment than anticipated. Safety concerns were limited, with amyloid imaging\u2010related abnormality\u2013related interruptions in 3.5%. More than half highly supported additional reimbursement for infusion\u2010related services and insurance coverage for apolipoprotein E (\n                      <jats:italic>APOE<\/jats:italic>\n                      ) testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>\n                      Early access to lecanemab appears feasible, yet infrastructure and financial hurdles remain. Dedicated reimbursement and insurance coverage for\n                      <jats:italic>APOE<\/jats:italic>\n                      testing may be essential for ensuring safer, more accessible, and sustainable use of this therapy in Japan.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Results from an online survey of 311 Japanese specialists prescribing lecanemab in its first year are reported.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Majority of wait times from first consultation to initial infusion were 1 to 3 months.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Tight affordability of infusion space and staffing was reported by one quarter.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Establishing additional medical fee for infusion management was highly expected.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Reimbursement of apolipoprotein E test in Japanese health insurance system was also demanded.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.70652","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:53:16Z","timestamp":1760971996000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Real\u2010world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers"],"prefix":"10.1002","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4351-9526","authenticated-orcid":false,"given":"Kenichiro","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Neuropathology Graduate School of Medicine The University of Tokyo  Tokyo Japan"},{"name":"Unit for Early and Exploratory Clinical Development The University of Tokyo Hospital  Tokyo Japan"},{"name":"Dementia Inclusion and Therapeutics The University of Tokyo Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-8167","authenticated-orcid":false,"given":"Yoshiki","family":"Niimi","sequence":"additional","affiliation":[{"name":"Unit for Early and Exploratory Clinical Development The University of Tokyo Hospital  Tokyo Japan"},{"name":"Dementia Inclusion and Therapeutics The University of Tokyo Hospital  Tokyo Japan"},{"name":"Department of Healthcare Economics and Health Policy Graduate School of Medicine The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Ihara","sequence":"additional","affiliation":[{"name":"Department of Neurology Tokyo Metropolitan Institute for Geriatrics and Gerontology  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Neurology Tokyo Metropolitan Institute for Geriatrics and Gerontology  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Institute of Medicine University of Tsukuba  Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuaki","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Institute of Medicine University of Tsukuba  Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Ibaraki Medical Center Tokyo Medical University  Inashiki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Public Health Yokohama City University School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensaku","family":"Kasuga","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics Brain Research Institute Niigata University  Niigata Japan"},{"name":"Department of Diagnostic Innovation Science National Center for Geriatrics and Gerontology  Obu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Yokohama Brain and Spine Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Awata","sequence":"additional","affiliation":[{"name":"Integrated Research Initiative for Living Well with Dementia Tokyo Metropolitan Institute for Geriatrics and Gerontology  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Osaka University Graduate School of Medicine  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwatsubo","sequence":"additional","affiliation":[{"name":"Department of Neuropathology Graduate School of Medicine The University of Tokyo  Tokyo Japan"},{"name":"Unit for Early and Exploratory Clinical Development The University of Tokyo Hospital  Tokyo Japan"},{"name":"Dementia Inclusion and Therapeutics The University of Tokyo Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"issue":"17","key":"e_1_2_11_2_1","first-page":"1631","article-title":"Lecanemab in Early Alzheimer's disease. reply","volume":"388","author":"Dyck CH","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_2_11_6_1","unstructured":"Ministry of Health Labour and Welfare.LEQEMBI Optimal Use Guideline [Article in Japanese]: Accessed on Dec 13 2023. (https:\/\/www.mhlw.go.jp\/content\/12404000\/001178607.pdf)"},{"key":"e_1_2_11_7_1","unstructured":"Ministry of Health Labour and Welfare.KISUNLA Optimal Use Guideline [Article in Japanese]: Accessed on Nov 13 2024. (https:\/\/www.mhlw.go.jp\/content\/10808000\/001330899.pdf)"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.159"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209402"},{"key":"e_1_2_11_11_1","unstructured":"MattkeS Hl\u00e1vkaJP YoongJ WangM GotoR.Assessing the preparedness of the Japanese health care system infrastructure for an Alzheimer's treatment.2019."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13348"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51880"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.94"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01568-8"},{"key":"e_1_2_11_16_1","unstructured":"Mix Online.Eisai FY2025 Q3 Financial Results Briefing. Accessed on February 9 2025. [Article in Japanese]. (https:\/\/www.mixonline.jp\/tabid55.html?artid=77869)"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100170"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.14945"},{"issue":"3","key":"e_1_2_11_19_1","first-page":"2","article-title":"Assessing the preparedness of the health care system infrastructure in six european countries for an Alzheimer's treatment","volume":"8","author":"Hlavka JP","year":"2019","journal-title":"Rand Health Q"},{"key":"e_1_2_11_20_1","unstructured":"OECD Data.Magnetic resonance imaging (MRI) units: Accessed on May 13 2024. (https:\/\/data.oecd.org\/healtheqt\/magnetic\u2010resonance\u2010imaging\u2010mri\u2010units.htm)"},{"key":"e_1_2_11_21_1","unstructured":"Central Social Insurance Medical Council Ministry of Health Labour and Welfare. (2023 December 13).On price calculation for new pharmaceuticals.(Meeting materials No. 23\u201012\u20102). [Article in Japanese]. Accessed on December 23 2023. (https:\/\/www.mhlw.go.jp\/content\/001179210.pdf)"},{"key":"e_1_2_11_22_1","unstructured":"Alzforum.Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial: Accessed on December 9 2024. (https:\/\/www.alzforum.org\/news\/conference\u2010coverage\/leqembi\u2010side\u2010effects\u2010no\u2010worse\u2010clinical\u2010use\u2010they\u2010were\u2010trial)"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100160"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12782"},{"key":"e_1_2_11_25_1","unstructured":"Biogen.FDA Accepts LEQEMBI\u00ae (lecanemab\u2010irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease. Accessed on December 9 2024. (https:\/\/investors.biogen.com\/news\u2010releases\/news\u2010release\u2010details\/fda\u2010accepts\u2010leqembir\u2010lecanemab\u2010irmb\u2010biologics\u2010license)"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03622-w"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:31:20Z","timestamp":1764160280000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/alz.70652"],"URL":"https:\/\/doi.org\/10.1002\/alz.70652","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70652"}}